News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
January 2019
-
Media ReleaseNovartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
-
Media ReleaseNovartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease- Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease- Sickle cell VOCs, which are triggered…
-
Media ReleaseNovartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
December 2018
-
Media ReleaseNovartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease-Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy…
-
Media ReleaseNovartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
-
Media ReleaseNovartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses- BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after…
-
Media ReleaseNovartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
-
Media ReleaseReal-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies- Promacta (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic…
-
Media ReleaseReal-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
-
Media ReleaseNovartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers- In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration…
-
Media ReleaseNovartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program-New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients-Crizanlizumab, a monthly infusion…
-
Media ReleaseNovartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
Pagination
- ‹ Previous page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- …
- 56
- › Next page